While Everyone Drooled Over SpaceX, These 3 Micro-Caps Were Quietly Doing Something Interesting

Look, we get it. SpaceX IPO'd at $135, popped 19%, made Elon the world's first trillionaire, and consumed every last brain cell on financial Twitter. But while the herd stampeded toward the biggest IPO in history, a few genuinely interesting small-caps were moving on fundamentals — not vibes. Let's talk about those.

$ACMR (ACM Research) is a semiconductor equipment maker with a market cap under $2B that cleans wafers using a proprietary single-wafer technology. It's almost entirely ignored by mainstream media because it doesn't make chips — it makes the machines that scrub them. With SMH posting its highest-ever weekly close per TheChartGuys and memory stocks leading NASDAQ, the upstream equipment play is criminally underappreciated. The catalyst: any uptick in leading-edge fab buildout in Asia directly benefits ACMR's order book, and a quarterly earnings beat could be the spark that gets it on institutional radars.

$ARQT (Arcutis Biotherapeutics) is a specialty dermatology biotech sitting at roughly $800M market cap with two FDA-approved products already on the market — Zoryve cream and foam for plaque psoriasis and seborrheic dermatitis. It's profitable on a product level, flying completely under the radar because, well, skin conditions don't generate hype. The catalyst here is simple: commercial uptake data from their Q2 report. If prescription volume is accelerating, this thing re-rates fast. Boring disease area, interesting chart.

$NBTX (Nanobiotix) is a Paris-based clinical-stage company — but it trades on NASDAQ, so it counts. It develops radioenhancers that make radiation therapy more effective, essentially turning existing cancer treatment infrastructure into something significantly more lethal to tumors. Market cap hovers around $400M. The catalyst is a partnership with Johnson & Johnson's oncology division that's already signed — milestone payments could hit the income statement before most people even Google the ticker. Three picks, zero hype, all business — which in this market is basically a personality disorder.